Drug Trial Radar · NCT04894994
FLX475 in Combination With Ipilimumab in Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Sep 3, 2021
Primary completion
Sep 13, 2022
Study completion Sep 13, 2022
Sponsor
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.
Conditions
- Advanced Melanoma
Interventions
FLX475Drug
Tablet
IpilimumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Approximately 1 year
- Safety and Tolerability as Measured by Number of Participants That Experienced Other Adverse EventsTime frame: Approximately 3 weeks
- Safety and Tolerability as Measured by Number of Participants That Experienced Serious Adverse EventsTime frame: Approximately 3 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
Washington University School of Medicine St. Louis
St Louis, Missouri
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.